Business
GSK Posts 5% Sales Growth and Targets £1.9 Billion in Cost Cuts to Fund Its Pipeline
Strong specialty-medicine sales lifted GSK's second quarter as the drugmaker doubles down on oncology — and braces for looming HIV patent losses.